1. Home
  2. EDUC vs SNGX Comparison

EDUC vs SNGX Comparison

Compare EDUC & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Educational Development Corporation

EDUC

Educational Development Corporation

N/A

Current Price

$1.32

Market Cap

10.7M

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.20

Market Cap

12.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDUC
SNGX
Founded
1965
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
12.3M
IPO Year
1995
2006

Fundamental Metrics

Financial Performance
Metric
EDUC
SNGX
Price
$1.32
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
19.2K
110.5K
Earning Date
01-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.63
N/A
Revenue
$34,191,000.00
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$1.02
52 Week High
$1.84
$6.23

Technical Indicators

Market Signals
Indicator
EDUC
SNGX
Relative Strength Index (RSI) 44.39 48.46
Support Level $1.25 $1.11
Resistance Level $1.35 $1.22
Average True Range (ATR) 0.05 0.07
MACD -0.00 -0.00
Stochastic Oscillator 28.00 34.72

Price Performance

Historical Comparison
EDUC
SNGX

About EDUC Educational Development Corporation

Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: